A Multicenter, Open-Label, Phase 1b Study to Assess the Safety and Define the Maximally Tolerated Dose of Epidural Resiniferatoxin Injection for the Treatment of Intractable Pain Associated With Cancer
Phase of Trial: Phase I
Latest Information Update: 25 Oct 2017
At a glance
- Drugs Resiniferatoxin (Primary)
- Indications Cancer pain
- Focus Adverse reactions
- Sponsors Sorrento Therapeutics
- 23 Aug 2017 Status changed from not yet recruiting to recruiting.
- 06 Jul 2017 New trial record
- 29 Jun 2017 According to a Sorrento Therapeutics media release, the U.S. FDA has authorized Investigational New Drug Application (IND) for Resiniferatoxin (RTX).